Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration.


Journal

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390

Informations de publication

Date de publication:
08 2020
Historique:
received: 17 07 2019
revised: 18 05 2020
accepted: 24 05 2020
pubmed: 21 7 2020
medline: 27 8 2021
entrez: 21 7 2020
Statut: ppublish

Résumé

Melanocortin-4-receptor (MC4R) gene codes for a G-protein-coupled receptor that is highly expressed in the hypothalamus and involved in the regulation of appetite. Single-nucleotide polymorphisms (SNPs) in the MC4R gene region have been associated with obesity, type 2-diabetes (T2D) and with antipsychotic-induced weight gain. Of these, rs17066842 (G>A) in the MC4R promoter region is the top variant associated with obesity and diabetes. In this study, we investigated the effect of rs17066842 on MC4R expression at various glucose concentrations using reporter gene expression in the SH-SY5Y cell line and regulation of MC4R expression in human cerebral organoids. We observed that higher glucose concentrations significantly reduced MC4R mRNA expression in SH-SY5Y cells. In addition, at high glucose concentrations, the luciferase reporter plasmid containing the MC4R promoter insert with the G-allele of rs170066842 showed significantly reduced activity compared to the A-allele carrying plasmid. The immediate early gene product, early growth-response 1 (EGR-1), was identified to bind to the sequence containing the G-allele at rs17066842 but not to the A-allele-containing sequence. Interestingly, in human induced pluripotent stem cell (hiPSC)-derived cerebral organoids, we observed increased MC4R expression in response to high glucose exposure. These opposite observations might suggest that glucose regulation is complex and may be cell-specific. This study provides evidence that rs17066842 regulates MC4R gene expression through binding of EGR-1 and that this process is influenced by glucose concentration.

Identifiants

pubmed: 32684494
pii: S0924-977X(20)30185-1
doi: 10.1016/j.euroneuro.2020.05.008
pii:
doi:

Substances chimiques

Receptor, Melanocortin, Type 4 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-48

Subventions

Organisme : Canadian Institutes for Health Research
ID : MOP 142192
Pays : International

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Li Qin (L)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada.

Arun K Tiwari (AK)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.

Clement C Zai (CC)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.

Natalie Freeman (N)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada.

Dongxu Zhai (D)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.

Fang Liu (F)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.

Harald Stachelscheid (H)

Berlin Institute of Health, Stem Cell Core Facility, 13353 Berlin, Germany; Charité - Universitätsmedizin Berlin, Charité-BIH Centrum Therapy and Research 13353 Berlin, Germany.

Philipp Mergenthaler (P)

Charité-Universitätsmedizin Berlin, Department of Experimental Neurology, Department of Neurology, Center for Stroke Research Berlin, 10117 Berlin, Germany; Berlin Institute of Health (BIH), 10178 Berlin, Germany.

James L Kennedy (JL)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.

Daniel J Müller (DJ)

Pharmacogenetics Research Clinic, Molecular Brain Science, Centre for Addiction and Mental Health, Toronto M5T 1R8, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada. Electronic address: daniel.mueller@camh.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH